Buy Toremifene Citrate Powder Online
Toremifene Citrate Powder is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body.
Toremifene Citrate Powder is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.
Buy toremifene Citrate Powder has already been covered that Toremifene is a SERM, and serves to block Estrogen at various receptor sites in certain tissues within the body. As a layman explanation.
Toremifene Citrate Powder pretends to be a fake Estrogen that occupies Estrogen receptors within breast tissue. With these receptors occupied by Toremifene, real Estrogen cannot perform their jobs there.
Toremifene Citrate Powder is also agonistic to Estrogen receptors in other tissues in the body (within the liver in particular). This means that whileToremifene will act as an anti-estrogen in breast tissue and the hypothalamus, it will act as an Estrogen within the liver. This can have beneficial impacts especially during an cycle, such as improving and shifting cholesterol levels into a more favorable range.
It has already been covered that Toremifene Citrate Powder is a SERM, and serves to block Estrogen at various receptor sites in certain tissues within the body (breast tissue in particular). As a layman explanation, Toremifene pretends to be a ‘fake’ Estrogen that occupies Estrogen receptors within breast tissue. With these receptors occupied by Toremifene, real Estrogen cannot perform their jobs there. Toremifene does not reduce total blood plasma levels of Estrogen. In addition to being antagonistic to Estrogen receptors in breast tissue, it is also antagonistic to Estrogen at the hypothalamus gland (this essentially ‘tricks’ the hypothalamus into thinking there is little or no circulating Estrogen levels in the body, causing it to increase its manufacture of so that it can utilize aromatization to restore these levels.
1. more than 5years Rich experience: Our company is a professional production leading factory in China in pharmaceutical area of many years.
2. Discreet package: The packing suits you best would be choosen to cross customs safely. also our warehouse have more than 1hundreds of packing methods ,Or if you have your own ideal way, it could be also taken into consideration .
3. Top quality: High quality guaranteed, once any problem is found, the package would be reshipped for you and some other products for free .
4. Security Shipping: Shipping by express (FedEx,UPS,DHL,EMS), by air.The most professional forwarder would be recommended for you.
5. Fast delivery: we hare stock ,so we can deliver your order in 4 hours when payment information was confirmed.
6. Quality service: we will give you warm after-sale service,if any question we will reply you at once .
7. Competitive prices: big discount under market price ,plz connect me ,a gift is ready for you
Toremifene Citrate Powder Dosage
Toremifene Citrate Powder is interchangeable with tamoxifen citrate (Nolvadex) while on cycle or in post-cycle therapy. 20mg of tamoxifen citrate = 60mg of toremifene citrate3 . From this Toremifene citrate can be extrapolated that for treatment and/or prevention of gynocomastia sixty milligrams should be sufficient for treatment. The recommended dosage for breast cancer treatment is one 60mg tablet administered once per day. During steroid treatment athletes and bodybuilders may use 30mg to 60mg per day
For use during post-cycle therapy users have anecdotally indicated that doses ranging between 60 and 120 mgs per day are average. Most users have reported when using Toremifene citrate for their post-cycle therapy they will administer the drug for a minimum of three weeks. A maximum length has not necessarily been established due to the few side effects associated with the compound. In this case, this compound can be run for as long as wanted with little to no concern being needed to be paid to potential side effects.
Terms: This product is intended for laboratory research use only. Read all terms and conditions of use before placing your order.
WARNING This product is a very potent chemical. This product is NOT for human use and can be harmful if ingested. This product is for research/laboratory use only. This product is NOT in a sterile solution and is NOT to be injected. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and should not be misbranded, misused or mislabeled as a drug, food or cosmetic.
The latter article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
|Description||Toremifene Citrate is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.|
|In vitro||Toremifene (7.5 mM) causes approximately 60% of the cells to exhibit morphologic characteristics typical of cells undergoing programmed death, or apoptosis in human breast cancer cells. Toremifene (5-10 mM) results in elevated levels of TRPM-2 and TGF beta 1 mRNAs in in vitro or in vivo grown tumor cells. Toremifene causes growth inhibition of estrogen-sensitive breast cancer cells by inducing some cells to undergo apoptosis and by inhibiting other cells from entering mitosis.  Toremifene induces a dose-dependent level of adducts that is lower than that observed for TAM. Toremifene significantly enhances endogenous DNA adduct formation.  Toremifene affects the cell turnover by inhibiting mitotic activity and modifying abundant spontaneous apoptosis in DMBA-induced rat mammary carcinoma. |
|In vivo||Toremifene Citrate Powder, at the highest tested dose, increases the incidence of hepatocellular carcinomas in the DEN-initiated groups to a level one-third that observed with Tamoxifen administration to DEN-initiated rats. Toremifene increases the incidence of hypernephromas in previously DEN-initiated rats.  Toremifene results in aneuploidy in 50% of the cells examined and compared with the 85% level induced by Tamoxifen in female Sprague-Dawley rats. |